Sai Parenteral's Limited, originally established as a private limited company in 2001, transitioned to a public company in January 2022. The company operates in the pharmaceutical sector, focusing on Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) services for domestic and international markets. Its diverse product portfolio spans complex pharmaceutical formulations addressing critical therapeutic needs across cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, and other key areas in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments.
Strategic acquisitions have played a significant role in the company’s growth. In 2016, it added Unit-I and Unit-II to its manufacturing base, launching Prefilled technology equipment in Unit-I by FY 2021. In 2022, it acquired two additional production facilities: Unit III, accredited by Australia’s TGA, and Unit IV, approved by PIC/S and WHO-GMP. These acquisitions enabled the company to expand its CDMO capabilities and establish a presence in both regulated and semi-regulated markets. The company began exporting products in 2023 and further enhanced its domestic operations in 2024 by acquiring Revat Laboratories as a wholly owned subsidiary. Moreover, it is slated to establish an international presence through Sai Parenterals Pte. Limited in Singapore in FY25.
Sai Parenteral's is planning an Initial Public Offering (IPO) to issue 3.5 million equity shares with a face value of ₹5 each, consisting of an Offer for Sale and a ₹285 crore Fresh Issue. With a comprehensive product portfolio, expanded global footprint, and focus on regulated markets, the company is positioning itself for robust growth in the pharmaceutical sector.
